NELFCD and hematologic disorder: In patients with liver disease and without renal impairment or concomitant hematologic disorders, serum β2-MG represents a non-specific marker of lymphocyte activation and proliferation, resulting in a Th-1–mediated immune response (Freni et al. 1997).